Medpace Holdings (MEDP) Prices 7M Common Stock IPO at $23/Share, at High-End of Expectations
- Global stocks sag as bond 'bloodbath' shows no sign of letting up
- UPDATE: Alphabet (GOOG) Tops Q3 EPS Views; Revs Strong
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
- Cirrus Logic, Inc. (CRUS) Q2 Results and Guidance Beat Estimates
- Amazon.com (AMZN) Misses Q3 EPS by 26c, Offers Q4 Guidance
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Medpace Holdings, Inc. (Nasdaq: MEDP) announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $23.00 per share. All of the shares of common stock are being offered by Medpace. In addition, Medpace has granted the underwriters a 30-day option to purchase up to an additional 1,050,000 shares of common stock from Medpace at the initial public offering price, less underwriting discounts and commissions. Medpace’s common stock is expected to begin trading on the NASDAQ Global Select Market on August 11, 2016 under the ticker symbol “MEDP,” and the offering is expected to close on August 16, 2016, subject to customary closing conditions.
NOTE: The company was previously expecting a range of $20 - $23 per share.
Medpace intends to use the net proceeds of this offering to repay a portion of its outstanding borrowings under its senior secured term loan facility.
Jefferies LLC and Credit Suisse Securities (USA) LLC are acting as joint lead book-running managers for the offering. UBS Securities LLC and Wells Fargo Securities, LLC are also acting as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated and William Blair & Company, L.L.C. are acting as co-managers for the offering.
Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its physician-led, high-science, and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,300 people across 35 countries.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ZTO Express (ZTO) IPO Opens Lower
- Collegium Pharma (COLL) Prices 5M Share Stock Offering for Proceeds of $80M
- GasLog Partners (GLOP) Tops Q3 EPS by 1c; Enters Agreement to Acquire GasLog Seattle
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, IPOs
Related EntitiesCredit Suisse, UBS, William Blair, Jefferies & Co, Robert W Baird, Wells Fargo, IPO
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!